SSY Group secures drug approval in China

SSY Group Limited announced that its Cupric Chloride has received registration approval from China's National Medical Products Administration. This approval designates Cupric Chloride as a bulk drug for market preparations, marking the third such approval for the company's PRC entities.

Cupric Chloride is a crucial component in Multi-Trace Elements Injection, primarily utilized for supplementing trace elements.